The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial

Autor:	Wei-Chen Tai, Shih-Cheng Yang, Chih-Chien Yao, Cheng-Kun Wu, An-Che Liu, Chen-Hsiang Lee, Yuan-Hung Kuo, Seng-Kee Chuah, Chih-Ming Liang
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	Helicobacter pylori infection Rabeprazole-containing high-dose dual therapy Rabeprazole-containing hybrid therapy Antibiotic susceptibility Adverse events Infectious and parasitic diseases RC109-216
Zdroj:	Infectious Diseases and Therapy, Vol 12, Iss 5, Pp 1415-1427 (2023)
Druh dokumentu:	article
ISSN:	2193-8229 2193-6382
DOI:	10.1007/s40121-023-00811-3
Popis:	Abstract Introduction High-dose dual therapy (HDDT) can attain acceptable eradication rates provided that the optimal doses, timing and treatment duration are applied. The existing evidence still shows inconsistent reports ( 90% eradication rates for first-line H. pylori eradication as 14-day rabeprazole-containing HT did. HDDT is a potentially beneficial combination, which involves only two drugs with mild adverse effects; more precise studies are urged to find answers regarding these failures. This clinical trial was registered retrospectively on 28 November, 2021, as ClinicalTrials.gov identifier: NCT05152004.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/13c47a02e8df4799a7631184a8026807 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.